Physician profile
Aaron Jasso
NPI 1811334246
$4,215.57
in general payments reported to CMS, 2019-2025
20 companies · $2,528 in 2025
The $2,528 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $200 · 2022: $124 · 2023: $146 · 2024: $1,217 · 2025: $2,528.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,500 · Food and Beverage: $1,288 · Travel and Lodging: $104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,500.00 |
| Food and Beverage | $1,287.70 |
| Travel and Lodging | $103.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,906.65 | 2023-2025 | |
| Harmony Biosciences LLC | $161.42 | 2023-2025 | Wakix |
| Mayne Pharma Commercial LLC | $147.79 | 2021 | |
| Axsome Therapeutics, INC. | $140.28 | 2025 | Auvelity |
| Novo Nordisk INC | $124.62 | 2021-2022 | |
| Alkermes, INC. | $110.29 | 2023-2025 | Aristada, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $102.31 | 2024-2025 | Austedo Xr, Austedo Xr |
| Ironshore Pharmaceuticals INC. | $88.65 | 2024 | |
| Lundbeck LLC | $76.17 | 2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $65.63 | 2024-2025 | Cobenfy |
| Neurocrine Biosciences, INC. | $61.55 | 2023-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $56.40 | 2023-2025 | Rexulti |
| Lilly USA, LLC | $48.06 | 2022-2023 | Mounjaro, Jardiance, Synjardy |
| Supernus Pharmaceuticals, INC. | $31.37 | 2025 | Qelbree |
| Braeburn INC. | $20.90 | 2024 | Brixadi |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $15.89 | 2025 | Invega Sustenna |
| Indivior INC. | $15.71 | 2025 | Sublocade |
| Genentech USA, INC. | $15.61 | 2021-2022 | |
| Organon LLC | $14.90 | 2021 | |
| Laborie Medical Technologies Corp. | $11.37 | 2025 | Optilume Bph Drug Coated Balloon Catheter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Jasso listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.